|
2010 rank (US$)
|
2010 Sales (US$ MN)
|
% Growth 2010 (LC$)
|
2009 Sales (US$ MN)
|
% Growth 2009 (LC$)
|
2008 Sales (US$ MN)
|
% Growth 2008 (LC$)
|
2007 Sales (US$ MN)
|
||
Global Market
|
0
|
791,449$
|
5.2
|
752,022$
|
6.7
|
727,067$
|
5.0
|
671,164$
|
||
Oncologics
|
1
|
55,972$
|
6.7
|
52,372$
|
8.8
|
49,438$
|
13.4
|
41,949$
|
||
Lipid Regulators
|
2
|
36,400$
|
2.0
|
35,281$
|
4.9
|
34,445$
|
(1.2)
|
34,141$
|
||
Respiratory Agents
|
3
|
35,926$
|
7.0
|
33,596$
|
11.0
|
31,186$
|
5.9
|
28,775$
|
||
Antidiabetics
|
4
|
34,429$
|
12.2
|
30,406$
|
13.4
|
27,548$
|
10.1
|
24,401$
|
||
Anti-ulcerants
|
5
|
27,972$
|
(6.5)
|
29,610$
|
0.6
|
30,032$
|
0.0
|
29,174$
|
||
Angiotensin II Antagonists
|
6
|
26,630$
|
4.5
|
25,209$
|
11.5
|
22,998$
|
13.3
|
19,418$
|
||
Antipsychotics
|
7
|
25,412$
|
9.0
|
23,248$
|
4.6
|
22,742$
|
7.7
|
20,693$
|
||
Autoimmune agents
|
8
|
20,710$
|
14.7
|
17,961$
|
18.0
|
15,612$
|
19.3
|
12,815$
|
||
Antidepressants
|
9
|
20,216$
|
3.4
|
19,416$
|
(1.3)
|
20,194$
|
1.1
|
19,581$
|
||
HIV Antivirals
|
10
|
15,432$
|
13.2
|
13,758$
|
14.9
|
12,280$
|
12.7
|
10,699$
|
||
Platelet Aggr. Inhibitors
|
11
|
15,244$
|
1.8
|
14,604$
|
9.0
|
13,647$
|
10.4
|
11,952$
|
||
Vitamins & minerals
|
12
|
12,971$
|
6.1
|
11,951$
|
9.5
|
11,374$
|
8.7
|
10,109$
|
||
Anti-epileptics
|
13
|
12,553$
|
(3.3)
|
12,995$
|
(19.8)
|
16,792$
|
9.8
|
15,136$
|
||
Narcotic analgesics
|
14
|
12,011$
|
6.4
|
11,235$
|
8.6
|
10,534$
|
8.9
|
9,530$
|
||
Cephalosporins & combs
|
15
|
11,466$
|
6.1
|
10,586$
|
6.9
|
10,188$
|
3.4
|
9,489$
|
||
Non-Narcotic Analgesics
|
16
|
10,986$
|
0.0
|
10,917$
|
7.5
|
10,896$
|
4.2
|
10,179$
|
||
Vaccines
|
17
|
10,972$
|
2.8
|
10,690$
|
(1.6)
|
11,172$
|
(0.6)
|
10,911$
|
||
Erythropoietins
|
18
|
10,596$
|
(2.3)
|
10,829$
|
(4.1)
|
11,486$
|
(13.0)
|
12,866$
|
||
Anti-Rheumatics,
Non-Steroidal
|
19
|
10,152$
|
3.6
|
9,668$
|
3.0
|
9,897$
|
3.6
|
9,318$
|
||
Multiple Sclerosis
|
20
|
9,844$
|
13.8
|
8,712$
|
16.8
|
7,716$
|
19.9
|
6,245$
|
Saturday, 25 February 2012
Top 20 Global Therapeutic Classes, 2010, Total Audited Markets, IMS data
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment